Phases Telehealth Platform Debuts to Address Female-Specific Peptide Wellness Needs
As reported by WWD Beauty, Los Angeles-based entrepreneurs Lana Elie-Meyers and Joseph Elie-Meyers have launched Phases. This new telehealth platform provides women with personalized peptide treatments designed to support various life stages, including postpartum health and menopause, while addressing conditions such as endometriosis and PCOS through a medically supervised digital interface.
Context from Industry Pulse
The launch of Phases coincides with a broader shift in the beauty and wellness sector toward medicalized, gender-specific solutions. While the industry is seeing major moves from established players like Estée Lauder Companies raising financial outlooks and Whoop entering Ulta Beauty, the peptide market remains a complex regulatory frontier. The recent efforts by U.S. Health Secretary Robert F. Kennedy Jr. to loosen restrictions on specific compounded peptides suggest a potential mainstreaming of these treatments. Phases is positioning itself at this intersection by leveraging telehealth to provide a structured, safe pathway for consumers seeking medical-grade wellness interventions outside of traditional retail environments.
"I just found that there was a gap in the market of everyone launching peptide options, but nothing felt unique to the female body."
The launch of Phases signals a shift in the peptide market toward specialized care for women. The platform was established by the husband-and-wife duo following Elie-Meyers’ personal health struggles during her postpartum period, where she utilized peptides to manage symptoms like brain fog and eczema. According to WWD Beauty, the service aims to fill a perceived void in the industry where peptide options rarely accounted for the specific hormonal and physiological needs of the female body.
Phases operates as a comprehensive telehealth gateway, connecting patients with physicians who review medical intakes before prescribing treatments. These prescriptions are fulfilled through partner compounding pharmacies. WWD Beauty notes that the initial product lineup consists of nine options delivered via nasal sprays or injections. These treatments target metabolism, sexual wellness, energy, and recovery, with pricing starting at 145 dollars per month.
Specific pharmaceutical offerings include tirzepatide blended with B12 or glycine, as well as NAD plus, oxytocin, and sermorelin. As WWD Beauty reports, the company emphasizes that these treatments are meant to be additive to a healthy lifestyle rather than standalone solutions. The executive team includes a former civil rights litigator who manages the regulatory complexities of the prescription peptide landscape.
The regulatory environment for these substances is evolving rapidly. WWD Beauty highlights recent moves by U.S. Health Secretary Robert F. Kennedy Jr. to ease restrictions on compounding pharmacies for specific peptides like BPC-157. This shift follows a period where the Food and Drug Administration transitioned from broad restrictions to focusing on safe, physician-led prescription channels for these increasingly popular wellness treatments.
The Industry Pulse Bottom Line
Phases represents the next step in the medicalization of wellness, turning to telehealth and compounding pharmacies to provide women with targeted peptide therapies that traditional beauty brands cannot currently offer.